DermTech Future Growth

Future criteria checks 1/6

DermTech is forecast to grow earnings and revenue by 13% and 16.7% per annum respectively while EPS is expected to grow by 36.2% per annum.

Key information

13.0%

Earnings growth rate

36.2%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate16.7%
Future return on equityn/a
Analyst coverage

Low

Last updated06 Mar 2024

Recent future growth updates

Recent updates

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02
Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Dec 28
Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Sep 18
Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Jun 14
Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10
Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08
Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11
Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10
Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02
Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics

Sep 15

We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth

Sep 03
We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth

DermTech: Transforming The Melanoma Diagnosis Landscape

Aug 31

DermTech: Becoming More Appealing, Despite Nosebleed Valuation

Aug 09

DermTech appoints former Myriad Genetics executive as new chief medical officer

Jun 16

We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 05
We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech initiated buy at BTIG on the potential of PLA test

May 03

DermTech rises 18% on report Cigna covering early melanoma detection test

Apr 27

Earnings and Revenue Growth Forecasts

NasdaqCM:DMTK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202625-78N/AN/A1
12/31/202522-73N/AN/A5
12/31/202417-77N/AN/A5
12/31/202315-101-78-77N/A
9/30/202314-110-88-86N/A
6/30/202314-120-94-91N/A
3/31/202314-118-96-92N/A
12/31/202215-117-99-95N/A
9/30/202215-115-99-97N/A
6/30/202214-106-91-88N/A
3/31/202213-93-80-76N/A
12/31/202112-78-65-62N/A
9/30/202111-63-48-46N/A
6/30/20219-52-40-38N/A
3/31/20217-45-34-32N/A
12/31/20206-36-31-29N/A
9/30/20205-31-30-28N/A
6/30/20205-27-28-26N/A
3/31/20204-21-23-22N/A
12/31/20193-20-18-18N/A
9/30/20192-18-13-13N/A
6/30/20192-14-9-8N/A
3/31/20193-13-8-8N/A
12/31/20182-10-8-8N/A
12/31/20172-8-6-6N/A
6/30/20140-6N/A-4N/A
3/31/20140-6N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DMTK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DMTK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DMTK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DMTK's revenue (16.7% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: DMTK's revenue (16.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DMTK's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.